Dianthus Therapeutics, Inc.: cash_and_restricted_cash

Value{"amount": 23022000, "concept": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "currency": "USD"}
Period (as of 2024-12-31)
Statuscurrent
EntityDianthus Therapeutics, Inc.
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference: 0000950170-25-037131 · Open the official SEC filing →
Retrieved: 2026-08-19T17:19:32.661739+02:00
Raw response sha256: f7bde1a401b286c74a2fd824ee1df541…
Also addressable by official identifiers: https://factanker.com/fact/sec/cik-0001690585/cash-and-restricted-cash/2024-12-31 (CIK, metric, reporting date)
Cite as: FACTANKER, https://factanker.com/fact/09bb38b6-73f2-4d14-9eef-a2b0c55e1a91

History

From the Record
32 US software companies haven’t lost money in a decade. One of them is steadier than all the rest.
Read the findingSearch 53 million companies